FRAME, External Support for Lower Limb Autologous Grafts

February 3, 2025 updated by: Vascular Graft Solutions Ltd.

Prospective, Multicenter Study Evaluating the Performance and Safety of FRAME, External Support for Lower Limb Autologous Grafts.

30 patients will be enrolled in a prospective, multi-center, one-arm study, enrolling patients with claudication and chronic limb ischemia scheduled for lower limb venous bypass grafting on clinical grounds with single segment autologous saphenous vein.

Subjects will be followed for 5 years, with follow up visits at 1, 3, 6, 12 months, 2, 3, 4, 5, years post operation.

Study Overview

Status

Suspended

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Indiana
      • Fort Wayne, Indiana, United States, 46804
        • Lutheran Hospital of Indiana
    • Maryland
      • Baltimore, Maryland, United States, 21201
        • University of Maryland Baltimore
    • New York
      • New York, New York, United States, 10029
        • Mount Sinai Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Patient scheduled for infrainguinal peripheral artery bypass surgery with single segment autogenous saphenous vein.
  2. Rutherford classification 3-6
  3. Adequate revascularization target defined as an infrainguinal arterial segment distal to the area of stenosis/occlusion which can support a distal anastomosis of a surgical bypass.
  4. Patient is able and willing to give their informed written consent.
  5. Patient is able and willing to comply with study follow up requirements.
  6. Patient is ≥ 18 years of age

Exclusion Criteria:

  1. Patients indicated for endovascular treatment
  2. Prior surgical bypass procedure in ipsilateral lower limb.
  3. Active ulcer/infection/gangrene at the intended distal anastomosis site.
  4. Severe vein varicosity
  5. Saphenous vein with external pressurized diameter of less than 3.5 mm or more than 8 mm.
  6. Spliced vein technique
  7. In-situ vein technique
  8. Pedal/plantar distal anastomosis
  9. Planned above ankle amputation on ipsilateral limb within 4 weeks of index procedure.
  10. Patients with history of hypercoagulable conditions.
  11. Patients with significant stenoses distal to the planned anastomotic site and any other known conditions that could adversely affect graft patency.
  12. Concomitant life-threatening disease likely to limit life expectancy to less than 2 years.
  13. Contraindication to recommended study medications
  14. Participating in any other investigational study for either drug or device which can influence collection of valid data under this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: FRAME
Vein graft to be treated with FRAME
External support for vein grafts in peripheral bypass surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary patency
Time Frame: 12 months
Freedom of vein graft from occlusion and clinically driven target lesion revascularization as measured by Doppler Ultrasound
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 31, 2026

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

June 27, 2019

First Submitted That Met QC Criteria

June 27, 2019

First Posted (Actual)

July 1, 2019

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 3, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peripheral Arterial Disease

Clinical Trials on FRAME

Subscribe